Savara Inc.'s Participation in Investor Conferences
Savara Inc. (NASDAQ: SVRA), a dedicated biopharmaceutical company focused on addressing rare respiratory diseases, has exciting news about their upcoming participation in significant investor healthcare conferences. These events are a great opportunity for Savara to showcase its efforts in the healthcare field and connect with potential investors.
Engagement in Fireside Chats
During these conferences, members of Savara's management team will engage in 1x1 meetings and participate in enlightening fireside chats. This format allows for in-depth discussions about the company’s innovative approaches and ongoing projects in the biopharmaceutical space.
Guggenheim 2nd Annual Healthcare Innovation Conference
One of the key events is the Guggenheim 2nd Annual Healthcare Innovation Conference. Savara will be presenting on November 10, 2025, at 8:30 a.m. ET. This event will attract attention from various stakeholders and offers a platform for Savara to provide insights into their advancements and product pipelines.
Jefferies London Healthcare Conference
Another notable event is the Jefferies London Healthcare Conference, scheduled for November 19, 2025, at 12:00 p.m. GMT. This conference is highly regarded within the industry and provides a strategic venue for Savara to discuss progress and future directions.
Webcasts and Archival Access
For those unable to attend, the live webcasts of these presentations will be accessible on Savara’s corporate website. Furthermore, the recorded sessions will be archived for 90 days, ensuring widespread access to the information shared during these important conversations.
About Savara Inc.
Savara Inc. is at the forefront of developing treatments for rare respiratory diseases. Their lead therapeutic candidate, MOLBREEVI, is an innovative recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) that is currently in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). This product is uniquely delivered through a proprietary investigational eFlow Nebulizer System specifically engineered to allow effective inhalation.
Company's Management Experience
The management team at Savara boasts extensive experience in pulmonary medicine and rare respiratory conditions, enabling them to identify unmet needs effectively and advance their product candidates toward approval and commercialization. Their commitment to improving patient outcomes is evident in every stage of development and presentation.
Contact Information
For further inquiries, interested parties can reach out directly to Savara Inc. The contact for media and investor relations is Temre Johnson, Executive Director of Corporate Affairs. You can contact them at ir@savarapharma.com.
Frequently Asked Questions
What is Savara Inc. focused on?
Savara Inc. is a biopharmaceutical company that specializes in rare respiratory diseases.
When will Savara present at the healthcare conferences?
Savara will present at the Guggenheim conference on November 10 and at the Jefferies London Healthcare Conference on November 19, 2025.
How can I view the webcasts of the presentations?
The live webcasts and recordings will be available on Savara's corporate website in the "Events & Presentations" section.
What is MOLBREEVI?
MOLBREEVI is Savara's lead candidate for treating autoimmune PAP and is in Phase 3 clinical trials.
Who can I contact for more information about Savara?
You can reach out to Temre Johnson at Savara Inc. via email at ir@savarapharma.com for any inquiries.
